Vor Biopharma Inc Dossier
Financial Snapshot
Revenue, profitability, returns, debt, and capital allocation
Revenue $0TTM through 31 Mar 2026
Net Income -$883.1MTTM through 31 Mar 2026
Free Cash Flow -$150.7MTTM through 31 Mar 2026
Margins
| Current |
|---|
Returns
146.0%ROE
-43.3%ROA
Balance Sheet Health
Debt / Equity0.00x
Current Ratio31.15x
Net Debt-$488.6Mnet cash position
Cash & Equivalents$491.5M
Quality Metrics
Earnings-Beat Rate50.0%
Dividend
No dividend
Segment Performance
No segment data available.
Filing Detail Members
This section is available to registered members. Create a free account or sign in to unlock the full breakdown.